Simplify Asset Management Inc. Raises Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Simplify Asset Management Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 23,079 shares of the medical research company’s stock after acquiring an additional 5,670 shares during the period. Thermo Fisher Scientific comprises 0.2% of Simplify Asset Management Inc.’s portfolio, making the stock its 17th biggest position. Simplify Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $11,571,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $7,505,000. Boston Trust Walden Corp grew its stake in Thermo Fisher Scientific by 9.7% in the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after purchasing an additional 3,873 shares in the last quarter. Xponance LLC increased its holdings in Thermo Fisher Scientific by 8.1% during the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after purchasing an additional 4,436 shares during the period. Hudson Value Partners LLC raised its position in Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock valued at $8,349,000 after purchasing an additional 3,317 shares in the last quarter. Finally, Merit Financial Group LLC grew its position in shares of Thermo Fisher Scientific by 34.0% during the 4th quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company’s stock worth $8,984,000 after buying an additional 3,934 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 52,053 shares of company stock worth $30,643,589 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.3%

Shares of Thermo Fisher Scientific stock opened at $588.17 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market cap of $217.47 billion, a P/E ratio of 31.64, a PEG ratio of 2.39 and a beta of 0.85. The firm’s 50 day moving average price is $529.37 and its 200-day moving average price is $509.58. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the company posted $4.28 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Analysts Set New Price Targets

Several research firms recently weighed in on TMO. Jefferies Financial Group restated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Barclays boosted their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.